Krajina: Bangladéš
Jazyk: angličtina
Zdroj: DGDA (Directorate General of Drug Administration)
Rosuvastatin
Unimed Unihealth Pharmaceuticals Ltd.
Rosuvastatin
10 mg
Tablet
CORESTIN CORESTIN TM (Rosuvastatin) PRESENTATION Corestinill 5 mg film-coated tablets. Each tablet contains Rosuvastatin calcium INN corresponding to 5mg rosuvastatin. Corestinill 10 mg film-coated tablets. Each tablet contains Rosuvastatin calcium INN corresponding to 10mg rosuvastatin. INDICATIONS Corestin is indicated for patients with primary hypercholesterolaemia (type lla including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type llb) as an adjunct to diet when response to diet and exercise is inadequate. Corestin reduces elevated LDL-cholesterol, total cholesterol, triglycerides and ApoB, and increases HDL-cholesterol. Corestin is also indicated in patients with homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis). METHOD OF ADMINISTRATION Before initiating treatment with Corestin, the patient should be placed on a standard cholesterol- lowering diet that should continue during treatment. The dose of Corestin should be individualised according to the goal of therapy and patient response, using current consensus guidelines. The usual start dose is Corestin 10 mg once daily and the majority of patients are controlled at this dose. A dose adjustment to 20 mg can be made after 4 weeks, if necessary Corestin at a dose of 40 mg should only be used in patients with severe hypercholesterolaemia (including those with familial hypercholesterolaemia) who do not achieve their treatment goal on 20 mg. Corestin may be given at any time of day, with or without food. USE IN CHILDREN Paediatric experience is limited to a small number of children (aged 8 years or above) with homozygous familial hypercholesterolaemia. Use in children should be super\/ised by specialists. USE IN THE ELDERLY No dose adjustment is necessary. DOSAGE IN PATIENTS WITH RENAL INSUFFICIENCY No dose adjustment is necessary in patients with mild to moderate renal impairment. For patients with severe renal impairment (CrCI <30 ml/min) the dose o Prečítajte si celý dokument